Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®.

Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P.

Adv Ther. 2019 Jul;36(7):1770. doi: 10.1007/s12325-019-00975-w. Epub 2019 Jun 9.

PMID:
31179515
2.

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®.

Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P.

Adv Ther. 2019 Jul;36(7):1756-1769. doi: 10.1007/s12325-019-00940-7. Epub 2019 Apr 2. Erratum in: Adv Ther. 2019 Jun 9;:.

PMID:
30941722
3.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.

Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

4.

Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.

Ahvenainen TV, Mäkinen NM, von Nandelstadh P, Vahteristo MEA, Pasanen AM, Bützow RC, Vahteristo PM.

Cancer. 2018 Dec 15;124(24):4650-4656. doi: 10.1002/cncr.31754. Epub 2018 Nov 13.

PMID:
30423196
5.

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

Jõgi R, Lähelmä S, Vahteristo M, Happonen A, Haikarainen J.

J Aerosol Med Pulm Drug Deliv. 2019 Apr;32(2):88-98. doi: 10.1089/jamp.2018.1463. Epub 2018 Oct 9.

6.

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.

Kirjavainen M, Mattila L, Vahteristo M, Korhonen J, Lähelmä S.

J Aerosol Med Pulm Drug Deliv. 2018 Oct;31(5):290-297. doi: 10.1089/jamp.2017.1437. Epub 2018 Mar 1.

7.

Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma.

Lähelmä S, Vahteristo M, Metev H, Taseva M, Stamatova N, Bartha A, Schlezák J, Sairanen U.

Respir Med. 2016 Nov;120:31-35. doi: 10.1016/j.rmed.2016.09.016. Epub 2016 Sep 25.

8.

Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.

Hantulik P, Wittig K, Henschel Y, Ochse J, Vahteristo M, Rytila P.

Pneumonol Alergol Pol. 2015;83(5):365-77. doi: 10.5603/PiAP.2015.0059.

9.

Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.

Lähelmä S, Sairanen U, Haikarainen J, Korhonen J, Vahteristo M, Fuhr R, Kirjavainen M.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):462-73. doi: 10.1089/jamp.2014.1195. Epub 2015 Mar 10.

10.

Entacapone and prostate cancer risk in patients with Parkinson's disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Mov Disord. 2015 Apr 15;30(5):724-8. doi: 10.1002/mds.26140. Epub 2015 Jan 16.

PMID:
25639262
11.

Entacapone did not Increase Prostate Cancer Risk or Mortality in Patients with Parkinson's Disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Value Health. 2014 Nov;17(7):A393. doi: 10.1016/j.jval.2014.08.870. Epub 2014 Oct 26. No abstract available.

12.

Pooled analysis of phase III with entacapone in Parkinson's disease.

Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K.

Acta Neurol Scand. 2014 Oct;130(4):239-47. doi: 10.1111/ane.12278. Epub 2014 Sep 3.

PMID:
25186800
13.

The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.

Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J.

Eur J Clin Pharmacol. 2012 Mar;68(3):281-9. doi: 10.1007/s00228-011-1121-5. Epub 2011 Sep 17.

PMID:
21927836
14.

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):756-60.

PMID:
20979935
15.

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.

Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J.

Clin Neuropharmacol. 2007 Nov-Dec;30(6):335-44. Erratum in: Clin Neuropharmacol. 2008 Jan-Feb;31(1):61.

PMID:
18090458
16.

Health risk assessment of indoor air pollution in Finnish ice arenas.

Salonen RO, Pennanen AS, Vahteristo M, Korkeila P, Alm S, Randell JT.

Environ Int. 2008 Jan;34(1):51-7. Epub 2007 Aug 22.

PMID:
17716732
17.

Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.

Dubakiene R, Nargela R, Sakalauskas R, Vahteristo M, Silvasti M, Lähelmä S.

Respiration. 2006;73(4):441-8. Epub 2005 Oct 7.

PMID:
16432294
18.

Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer.

Randell J, Saarinen A, Walamies M, Vahteristo M, Silvasti M, Lähelmä S.

Respir Med. 2005 Dec;99(12):1485-93. Epub 2005 Oct 11.

19.

Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.

Lähelmä S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, Ranki-Pesonen M.

Br J Clin Pharmacol. 2005 Feb;59(2):167-73.

20.

Comparison of two budesonide dry powder inhalers in the treatment of asthma in children.

Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Njå F, Hyldebrandt N; Study Group.

J Aerosol Med. 2004 Spring;17(1):15-24.

PMID:
15120009
21.

The remediation of mold damaged school--a three-year follow-up study on teachers' health.

Patovirta RL, Husman T, Haverinen U, Vahteristo M, Uitti JA, Tukiainen H, Nevalainen A.

Cent Eur J Public Health. 2004 Mar;12(1):36-42.

PMID:
15068207
22.

Indoor air microbes and respiratory symptoms of children in moisture damaged and reference schools.

Meklin T, Husman T, Vepsäläinen A, Vahteristo M, Koivisto J, Halla-Aho J, Hyvärinen A, Moschandreas D, Nevalainen A.

Indoor Air. 2002 Sep;12(3):175-83.

PMID:
12244747
23.

Comparison of inflammatory elements in nasal lavage and induced sputum following occupational exposure to moldy-building microbes.

Purokivi M, Hirvonen MR, Roponen M, Randell J, Vahteristo M, Tukiainen H.

Inhal Toxicol. 2002 Jun;14(6):653-62.

PMID:
12119074
24.

Comparison of two-level and three-level classifications of moisture-damaged dwellings in relation to health effects.

Haverinen U, Husman T, Vahteristo M, Koskinen O, Moschandreas D, Nevalainen A, Pekkanen J.

Indoor Air. 2001 Sep;11(3):192-9.

PMID:
11521504
25.

Chernobyl fallout and outcome of pregnancy in Finland.

Auvinen A, Vahteristo M, Arvela H, Suomela M, Rahola T, Hakama M, Rytömaa T.

Environ Health Perspect. 2001 Feb;109(2):179-85.

26.

Analysis of moisture findings in the interior spaces of Finnish housing stock.

Chelelgo J, Haverinen U, Vahteristo M, Koivisto J, Husman T, Nevalainen A, Jääskeläinen E.

J Air Waste Manag Assoc. 2001 Jan;51(1):69-77.

PMID:
11218427
27.

Cancer incidence around an oil refinery as an example of a small area study based on map coordinates.

Pekkanen J, Pukkala E, Vahteristo M, Vartiainen T.

Environ Res. 1995 Nov;71(2):128-34.

PMID:
8977621
28.

Prevalence and characteristics of children with chronic respiratory symptoms in eastern Finland.

Timonen KL, Pekkanen J, Korppi M, Vahteristo M, Salonen RO.

Eur Respir J. 1995 Jul;8(7):1155-60.

Supplemental Content

Loading ...
Support Center